Access read The price is not the news, the formulary position is. Denosumab biosimilars are already crowded, with at least three sets approved in the past year, and in a crowded biosimilar market a lower list price moves almost nothing on its own. What moves share is being the preferred product when a prescription is written, and Accord secured that on Cigna’s pharmacy benefit three weeks before launch, with the medical benefit following in September. Sequencing a launch behind confirmed preferred status, rather than launching and negotiating afterwards, is the discipline that separates biosimilars that take share from biosimilars that merely exist. One exposure worth flagging: these are the first products Intas has developed and manufactured entirely in house, which is a real margin advantage and also concentrates manufacturing in India in the same week Washington threatened tariffs of 100 percent from August 2028 on foreign-made generics. Whether biosimilars fall inside that policy is unresolved, and the answer will matter more to this launch than the list price does.